secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001104659-24-112054
Event type: m_and_a
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 3.02, 5.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics merges with Crescent in reverse acquisition; uproleselan trial fails
--------------------------------------------------------------------------------

- Crescent stockholders will own ~86.21% of combined company; GlycoMimetics stockholders ~13.79%.
- Concurrent $200M PIPE financing from institutional investors; closing conditioned on merger.
- NCI Phase 2/3 trial of uproleselan in AML failed to show statistically significant improvement in EFS or OS.
- Merger expected to close in Q2 2025; combined company to be led by Crescent's CEO and board.
- Support agreements cover ~98% of Crescent stock and ~9% of GlycoMimetics stock; 180-day lock-up.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000110465924112054/0001104659-24-112054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000110465924112054/tm2427013d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-112054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer